AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...
Non-medical switching policies that mandate biosimilar use for inflammatory arthritis do not appear to increase the use of ...
About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...
(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...
Dr. Beth Jonas answers the question: 'Anti-TNF Meds For Rheumatoid Arthritis?' — -- Question: What are anti-tumor necrosis factor (anti-TNF) medications and how are they used to treat rheumatoid ...
A Colorado panel voted Friday to cap the price for a best-selling drug from Amgen. It is one of four states that have passed ...
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...
Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback